Technical conditions have come together in biotech (SPBIO), indicating we’re at the danger point.
At this juncture, risk is least for short positioning.
Price action can go either way. However, the cost of being wrong (stop being hit) has been minimized.
This past week saw the biotech index retrace to a Fibonacci 23.6%, level and stall. Yesterday’s action was in a narrow range; potentially testing for more upside.
That (upside) didn’t happen.
Such a shallow retrace is rare. More typical is at least a 38.2%, level being tested before price reverses and heads lower.
If the index heads lower from here, that shallow retrace points to significant (major) weakness.
The daily of SPBIO is below with the 23.6% shown:
We’re going the compress the time-scale and invert the chart. Note the Fibonacci time correlation between price spikes:
Taking those 34-days and having the market itself define what’s important, it’s possible we have a trading channel as shown:
Prior updates have also shown SPBIO got into up-thrust (reversal) condition as it tested the retrace level.
Yesterday’s action (narrow range, no new daily high) was consistent with that assessment.
A significant, immense, fundamental bearish case has already been built for biotech.
As Reiner Fuellmich put it, he’s working to bring ‘crimes against humanity’ lawsuits to those who are complicit in the largest scam and potential genocide in world history.
If the numbers can be believed (even if they’re wrong, they’re huge) nearly 1-Billion people have been injected.
Of course, not everyone in the sector is complicit.
Even so, years ago (July 2015) when biotech reached a major high, David Stockman analyzed the sector.
He concluded the fundamentals were so bad, the entire sector could be summed up as ‘two trillion dollars of bottled air’.
We’ll have to figure not much has changed and/or, it’s probably worse.
Meanwhile, the insanity keeps piling up.
This just out a couple of days ago; a story about mixing the speck injections together. Just like you would do with a cake recipe. What could go wrong … unless it’s planned that way.
We’ll know pretty quickly next week if we’re at the inflection point. The expectation is for lower action in SPBIO.
The LABD (3X inverse SPBIO) stop is tight and in the market. There have been no position changes since the last ‘project update‘ (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Pingback: The 38.2%, Retrace « The Danger Point